Since the legalisation of medical cannabis in Australia in 2016, the medical application has been a hot topic in the media, across politics and in the medical health space.
Research and development is at the core of everything we do at ANTG, and it’s our role to provide you with evidence and tools to help make informed medical decisions.
We’re dedicated to discovering the full potential of cannabinoid medicines in treating disease and improving lives. The individual health and wellbeing of people are at the heart of everything we do.
That’s why we partner with leading scientists, medical institutions and research centres to improve medical knowledge and efficacy. Our research partners include the University of Newcastle and the National Institute for Complementary Medicines at Western Sydney University amongst many others. Together, we’re expanding our understanding of additional uses for cannabinoids, not only to help people but to shape the future of the industry.
We are also proud to have recently become the first Australian member of the Global Cannabis Partnership. The GCP is an international initiative that focuses on the establishment of worldwide corporate social responsibility (CSR) standards and informed consumption of legal cannabis.
Learn more about this exciting field in the articles below.
ANTG’s James Gaskell joins 2SER Breakfast on 107.3 to discuss his thoughts on ACT’s recent legalisation of cannabis, the conflict of state vs federal laws, and the medicinal cannabis industry in Australia and abroad.
A report into the Narcotic Drugs Act (ND Act) has recommended several changes to medical cannabis regulation in Australia.
The Morrison government is prioritising the medicinal cannabis industry and from September the Office of Drug Control will fast track new licences for all projects that have a big impact on exports, jobs or industry growth.